Ligand Acquires Portfolio Of Synthetic Royalty And Milestone Rights From CorMatrix Cardiovascular For $17.5M

Ligand Pharmaceuticals Incorporated announces the acquisition of economic rights to multiple programs owned by CorMatrix.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news